Ryan J. Winstead
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ryan J. Winstead has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Gaurav Gupta
Virginia Commonwealth University, Richmond, VA
5 shared publications - Dhiren Kumar
Virginia Commonwealth University
4 shared publications - Idris Yakubu
Division of Transplant Surgery, Virginia Commonwealth University Richmond, Virginia, USA
4 shared publications - Chelsey Chenxi Song
Department of Pharmacy Virginia Commonwealth University Health System Richmond VA USA
3 shared publications Andrew Brown
Hume‐Lee Transplant Center Virginia Commonwealth University Health Richmond VA USA
2 shared publications- Andrew Brown
Department of Pharmacy Virginia Commonwealth University Health System Richmond VA USA
2 shared publications
Latest Publications
- Open Access
- 18 August 2021
- Published by MDPI AG in Transplantology
- Vol. 2 (3) , 291-293
Effect of Remdesivir on COVID-19 PCR Positivity and Cycle Threshold in Kidney Transplant Recipients
Information regarding Coronavirus disease 2019 in the transplant population is lacking. Recently it has been suggested that cycle threshold values obtained on polymerase chain reaction tests may serve as a marker of disease severity with lower values (i.e., higher viral load) being associated with higher mortality. This study was done to assess the impact of remdesivir use on the time to a negative COVID-19 PCR as well as the degree of change between two Ct’s based on treatment. A total of 30 kidney transplant patients with a new diagnosis of COVID-19 were assessed. Serial PCR results were followed from the time of diagnosis then every 2–4 weeks until negative. In patients who received remdesivir immediately after COVID-19 confirmation compared to no remdesivir, time to negative PCR was not statistically different with a median duration of 57 days in both groups (p = 0.369). The change in the Ct between the first and the second PCR test was also not statistically different between groups with a median change of 18.4 cycles in the remdesivir group and 15.7 cycles without remdesivir (p = 0.516). The results of this small single-center analysis suggest that remdesivir may not be beneficial in shortening time to a negative COVID-19 PCR.
- 18 August 2021
- Published by MDPI AG in Transplantology
- Vol. 2 (3) , 291-293
Open AccessEffect of Remdesivir on COVID-19 PCR Positivity and Cycle Threshold in Kidney Transplant Recipients
Information regarding Coronavirus disease 2019 in the transplant population is lacking. Recently it has been suggested that cycle threshold values obtained on polymerase chain reaction tests may serve as a marker of disease severity with lower values (i.e., higher viral load) being associated with higher mortality. This study was done to assess the impact of remdesivir use on the time to a negative COVID-19 PCR as well as the degree of change between two Ct’s based on treatment. A total of 30 kidney transplant patients with a new diagnosis of COVID-19 were assessed. Serial PCR results were followed from the time of diagnosis then every 2–4 weeks until negative. In patients who received remdesivir immediately after COVID-19 confirmation compared to no remdesivir, time to negative PCR was not statistically different with a median duration of 57 days in both groups (p = 0.369). The change in the Ct between the first and the second PCR test was also not statistically different between groups with a median change of 18.4 cycles in the remdesivir group and 15.7 cycles without remdesivir (p = 0.516). The results of this small single-center analysis suggest that remdesivir may not be beneficial in shortening time to a negative COVID-19 PCR.
- 28 June 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13678
Changes in cytomegalovirus‐specific T‐cell immunity with immunomodulation in serodiscordant high‐risk transplant recipients
Cytomegalovirus (CMV) infections can cause significant morbidity and mortality among serodiscordant (D+/R-) transplant recipients. CMV specific T cell immunity has been shown in previous studies to predict those at highest risk for CMV events. This is a retrospective study encompassing data on CMV discordant solid organ transplant recipients who received at least one CMV specific T cell immunity assay (CD4 and CD8) prior to cessation of universal prophylaxis. Our study demonstrated that patients with low CMV CD4/CD8 had improved CMV T cell immunity with changes to maintenance immunosuppression.
- 28 June 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13678
Changes in cytomegalovirus‐specific T‐cell immunity with immunomodulation in serodiscordant high‐risk transplant recipients
Cytomegalovirus (CMV) infections can cause significant morbidity and mortality among serodiscordant (D+/R-) transplant recipients. CMV specific T cell immunity has been shown in previous studies to predict those at highest risk for CMV events. This is a retrospective study encompassing data on CMV discordant solid organ transplant recipients who received at least one CMV specific T cell immunity assay (CD4 and CD8) prior to cessation of universal prophylaxis. Our study demonstrated that patients with low CMV CD4/CD8 had improved CMV T cell immunity with changes to maintenance immunosuppression.
- 20 January 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13570
Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction
Background: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a new agent approved for CMV prophylaxis in hematopoietic stem cell transplantation and is associated with less toxicity. This study aims to assess the effectiveness and safety of letermovir in solid organ transplantation.Methods: A single‐center, matched cohort study was performed on 31 transplant recipients who were converted from valganciclovir to letermovir from November 2017 to June 2020. The primary outcome was the rate of CMV breakthrough infections while on prophylaxis. Secondary outcomes included rate of leukopenia, doses of immunosuppression, rejection, non‐CMV infection, and renal function. Statistical analyses of continuous variables included the student's t‐test, ANOVA test, and Wilcoxon Signed Rank test. Categorical data were analyzed with chi‐square test and Fisher’s Exact test.Results: There was no difference in the rate of CMV breakthrough between patients on letermovir (8.7%) and valganciclovir (13.5%), (P = .7097). After conversion to letermovir, patients required lower tacrolimus doses at ‐3.34 mg (SD‐1.3, P = .0273), between conversion and day 7. Transplant Infectious Disease The median difference in tacrolimus trough concentrations from conversion to day seven was 9.1 ng/ml [4.9, 16.95] (P = .0002). Leukopenia improved by 1.8 109/L [1.08, 4.85] (P < .0001).Conclusions: Patients converted from valganciclovir to letermovir did not show an increased rate of CMV breakthrough compared to a historical, matched cohort of patients remaining on valganciclovir. A significant drug interaction was noted with tacrolimus, leading to a recommendation to reduce the dose by 40‐50% upon initiation of letermovir.
- 20 January 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13570
Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction
Background: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a new agent approved for CMV prophylaxis in hematopoietic stem cell transplantation and is associated with less toxicity. This study aims to assess the effectiveness and safety of letermovir in solid organ transplantation.Methods: A single‐center, matched cohort study was performed on 31 transplant recipients who were converted from valganciclovir to letermovir from November 2017 to June 2020. The primary outcome was the rate of CMV breakthrough infections while on prophylaxis. Secondary outcomes included rate of leukopenia, doses of immunosuppression, rejection, non‐CMV infection, and renal function. Statistical analyses of continuous variables included the student's t‐test, ANOVA test, and Wilcoxon Signed Rank test. Categorical data were analyzed with chi‐square test and Fisher’s Exact test.Results: There was no difference in the rate of CMV breakthrough between patients on letermovir (8.7%) and valganciclovir (13.5%), (P = .7097). After conversion to letermovir, patients required lower tacrolimus doses at ‐3.34 mg (SD‐1.3, P = .0273), between conversion and day 7. Transplant Infectious Disease The median difference in tacrolimus trough concentrations from conversion to day seven was 9.1 ng/ml [4.9, 16.95] (P = .0002). Leukopenia improved by 1.8 109/L [1.08, 4.85] (P < .0001).Conclusions: Patients converted from valganciclovir to letermovir did not show an increased rate of CMV breakthrough compared to a historical, matched cohort of patients remaining on valganciclovir. A significant drug interaction was noted with tacrolimus, leading to a recommendation to reduce the dose by 40‐50% upon initiation of letermovir.
- Open Access
- 13 September 2020
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (2)
Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow‐up period of 6 months, overall patients had a statistically significant improvement in weight by −2.95 kg [SD 3.54, P = <.0001 (CI: 3.53, 1.50)] as well as hypomagnesemia 0.13 [SD 1.73, P = .0004 (CI: 0.06, 0.20)]. Overall insulin usage declined by −3.7 units [SD 22.8, P = .17]. 14% of patients had at least one urinary tract infection although this rate is not different (~20%) than that reported historically in this high‐risk population.
- 13 September 2020
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (2)
Open AccessEarly initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow‐up period of 6 months, overall patients had a statistically significant improvement in weight by −2.95 kg [SD 3.54, P = <.0001 (CI: 3.53, 1.50)] as well as hypomagnesemia 0.13 [SD 1.73, P = .0004 (CI: 0.06, 0.20)]. Overall insulin usage declined by −3.7 units [SD 22.8, P = .17]. 14% of patients had at least one urinary tract infection although this rate is not different (~20%) than that reported historically in this high‐risk population.
- 28 January 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (3) , e13791
Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression
- 28 January 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (3) , e13791
Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression
- 3 June 2019
- Published by SAGE Publications in Progress in Transplantation
- Vol. 29 (3) , 220-224
Outcomes of Lung Transplantation for Cystic Fibrosis in the Setting of Extensively Drug-Resistant Organisms
Introduction: Since the largest study on extensively drug-resistant organisms and lung transplantation in patients with cystic fibrosis, there have been innovations and advancements in the treatment of Pseudomonas aeruginosa. Research Question: What differences exist for patients with cystic fibrosis with a history of extensively drug-resistant infections who undergo lung transplantation despite treatment advances with antimicrobial therapy? Study Design: Two-center, retrospective, cohort study conducted in 44 patients with cystic fibrosis chronically infected with extensively drug-resistant organisms who received a lung transplant from January 2008 through August 2016. Patients in the resistant cohort were chronically infected with pan-resistant P aeruginosa, polymyxin-sensitive only, or sensitive to 2 antibiotic classes (polymyxin plus one other); remaining patients with more susceptible P aeruginosa or no P aeruginosa remained in the control cohort. The primary outcome is a composite of patient survival, retransplantation, chronic lung allograft dysfunction, and acute rejection 12 months posttransplant. Categorical variables were analyzed using χ2 testing. The independent samples t test was utilized for continuous variables. Results: There was no difference in the primary outcome (40% vs 37%, P = .831). Differences between patient survival (84% vs 95%, P = .487), the incidence of acute rejection (20% vs 33%, P = .323), and the incidence of chronic lung allograft rejection (12% vs 5%, P = .441) were not different between groups. Discussion: Recipients chronically infected with an extensively resistant P aeruginosa had similar outcomes compared to those infected with more sensitive organisms.
- 3 June 2019
- Published by SAGE Publications in Progress in Transplantation
- Vol. 29 (3) , 220-224
Outcomes of Lung Transplantation for Cystic Fibrosis in the Setting of Extensively Drug-Resistant Organisms
Introduction: Since the largest study on extensively drug-resistant organisms and lung transplantation in patients with cystic fibrosis, there have been innovations and advancements in the treatment of Pseudomonas aeruginosa. Research Question: What differences exist for patients with cystic fibrosis with a history of extensively drug-resistant infections who undergo lung transplantation despite treatment advances with antimicrobial therapy? Study Design: Two-center, retrospective, cohort study conducted in 44 patients with cystic fibrosis chronically infected with extensively drug-resistant organisms who received a lung transplant from January 2008 through August 2016. Patients in the resistant cohort were chronically infected with pan-resistant P aeruginosa, polymyxin-sensitive only, or sensitive to 2 antibiotic classes (polymyxin plus one other); remaining patients with more susceptible P aeruginosa or no P aeruginosa remained in the control cohort. The primary outcome is a composite of patient survival, retransplantation, chronic lung allograft dysfunction, and acute rejection 12 months posttransplant. Categorical variables were analyzed using χ2 testing. The independent samples t test was utilized for continuous variables. Results: There was no difference in the primary outcome (40% vs 37%, P = .831). Differences between patient survival (84% vs 95%, P = .487), the incidence of acute rejection (20% vs 33%, P = .323), and the incidence of chronic lung allograft rejection (12% vs 5%, P = .441) were not different between groups. Discussion: Recipients chronically infected with an extensively resistant P aeruginosa had similar outcomes compared to those infected with more sensitive organisms.
- 1 April 2019
- Published by AACN Publishing in Critical Care Nurse
- Vol. 39 (2) , 29-43
Overview of Pharmacological Considerations in Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation has become more widely used in recent years. Although this technology has proven to be lifesaving, it is not devoid of complications contributing to significant morbidity and mortality. Nurses who care for patients receiving extracorporeal membrane oxygenation should further their understanding of changes in medication profiles due to complex interactions with the extracorporeal membrane oxygenation circuitry. The aim of this comprehensive review is to give nurses a better understanding of analgesic, sedative, anti-infective, and anticoagulation medications that are frequently used to treat patients receiving extracorporeal membrane oxygenation.
- 1 April 2019
- Published by AACN Publishing in Critical Care Nurse
- Vol. 39 (2) , 29-43
Overview of Pharmacological Considerations in Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation has become more widely used in recent years. Although this technology has proven to be lifesaving, it is not devoid of complications contributing to significant morbidity and mortality. Nurses who care for patients receiving extracorporeal membrane oxygenation should further their understanding of changes in medication profiles due to complex interactions with the extracorporeal membrane oxygenation circuitry. The aim of this comprehensive review is to give nurses a better understanding of analgesic, sedative, anti-infective, and anticoagulation medications that are frequently used to treat patients receiving extracorporeal membrane oxygenation.
- 5 March 2018
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 45 (3) , 452-456
Factor VIIa administration in orthotopic heart transplant recipients and its impact on thromboembolic events and post-transplant outcomes
Recombinant, activated factor VIIa (rFVIIa) is used during cardiac surgeries to mitigate refractory coagulopathic bleeding. The purpose of this study was to examine whether rFVIIa use in orthotopic heart transplant (OHT) recipients was associated with a higher incidence of thromboembolic (TE) events compared to patients who did not. A single-center, retrospective, cohort study was performed on OHT recipients who received rFVIIa for refractory coagulopathic bleeding from January 2013 to December 2015. Patients were evaluated for up to 6 months after transplantation and assessed for TE events, rejection, readmissions, graft survival, and patient survival. Categorical variables were analyzed using the Chi square test while student’s t or ANOVA testing was utilized for continuous variables. Of the 62 patients who met inclusion criteria, 27 patients received rFVIIa, and 35 patients were selected for the control group. The overall incidence of TE events was not significantly different between patients who received rFVIIa compared to patients in the control group (14.8% vs 11.4%) (p = 0.69). Within 14 days, 14.81% of rFVIIa patients suffered a TE event compared to 5.7% of the control group (p = 0.23). Rejection, readmissions, graft survival, and patient survival were not significantly different at any time points. Use of rFVIIa in heart transplantation showed no difference in the overall rate of TE events, however, there was a nonsignificant trend toward higher risk of early TE development in the rFVIIa group compared to the control group.
- 5 March 2018
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 45 (3) , 452-456
Factor VIIa administration in orthotopic heart transplant recipients and its impact on thromboembolic events and post-transplant outcomes
Recombinant, activated factor VIIa (rFVIIa) is used during cardiac surgeries to mitigate refractory coagulopathic bleeding. The purpose of this study was to examine whether rFVIIa use in orthotopic heart transplant (OHT) recipients was associated with a higher incidence of thromboembolic (TE) events compared to patients who did not. A single-center, retrospective, cohort study was performed on OHT recipients who received rFVIIa for refractory coagulopathic bleeding from January 2013 to December 2015. Patients were evaluated for up to 6 months after transplantation and assessed for TE events, rejection, readmissions, graft survival, and patient survival. Categorical variables were analyzed using the Chi square test while student’s t or ANOVA testing was utilized for continuous variables. Of the 62 patients who met inclusion criteria, 27 patients received rFVIIa, and 35 patients were selected for the control group. The overall incidence of TE events was not significantly different between patients who received rFVIIa compared to patients in the control group (14.8% vs 11.4%) (p = 0.69). Within 14 days, 14.81% of rFVIIa patients suffered a TE event compared to 5.7% of the control group (p = 0.23). Rejection, readmissions, graft survival, and patient survival were not significantly different at any time points. Use of rFVIIa in heart transplantation showed no difference in the overall rate of TE events, however, there was a nonsignificant trend toward higher risk of early TE development in the rFVIIa group compared to the control group.
- 1 January 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (1) , 171-177
Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors
Traditional immunosuppressive regimens (ISR) used in lung transplantation rely on calcineurin inhibitors (CNI) that occasionally cause severe adverse reactions necessitating discontinuation. Belatacept is a novel costimulation antagonist approved for use in renal transplantation which lacks data in lung transplantation. This series aims to describe the response to belatacept ISR in 11 lung transplantation recipients after CNI failure. Single center, retrospective medical record review of adult lung transplant recipients (LTR) before and after conversion to belatacept-based ISR. Patients were evaluated at fixed time points before and after belatacept initiation. Primary outcome was incidence of acute cellular rejection (ACR). Secondary outcomes included incidence of infection, Chronic Lung Allograft Dysfunction (CLAD) progression, death, change in mean arterial pressure (MAP) and estimated glomerular filtration rate (eGFR). Eleven LTRs received belatacept with a mean of 246 (91-1064) days of follow-up after conversion. Four were changed to belatacept for thrombotic thrombocytopenic purpura; 3 for posterior reversible encephalopathy syndrome; 2 for recurrent ACR; 1 for CLAD; and 1 for renal-sparing. ACR was not different before and after belatacpet (p=0.17). Mean eGFR was significantly higher postbelatacept (32.53 vs 45.26, p=0.04). Mean incidence of infections (24.4% vs 16.0%, p=0.55), and MAP (97.5 vs 92.1 p=0.38), were not different. Progression of CLAD occurred in 2 patients. At the end of follow-up, 7/11 patients were alive. Belatacept-based ISR appear to produce reasonable results in LTRs who fail CNI-based ISR. Larger prospective trials appear warranted in lung transplantation.
- 1 January 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (1) , 171-177
Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors
Traditional immunosuppressive regimens (ISR) used in lung transplantation rely on calcineurin inhibitors (CNI) that occasionally cause severe adverse reactions necessitating discontinuation. Belatacept is a novel costimulation antagonist approved for use in renal transplantation which lacks data in lung transplantation. This series aims to describe the response to belatacept ISR in 11 lung transplantation recipients after CNI failure. Single center, retrospective medical record review of adult lung transplant recipients (LTR) before and after conversion to belatacept-based ISR. Patients were evaluated at fixed time points before and after belatacept initiation. Primary outcome was incidence of acute cellular rejection (ACR). Secondary outcomes included incidence of infection, Chronic Lung Allograft Dysfunction (CLAD) progression, death, change in mean arterial pressure (MAP) and estimated glomerular filtration rate (eGFR). Eleven LTRs received belatacept with a mean of 246 (91-1064) days of follow-up after conversion. Four were changed to belatacept for thrombotic thrombocytopenic purpura; 3 for posterior reversible encephalopathy syndrome; 2 for recurrent ACR; 1 for CLAD; and 1 for renal-sparing. ACR was not different before and after belatacpet (p=0.17). Mean eGFR was significantly higher postbelatacept (32.53 vs 45.26, p=0.04). Mean incidence of infections (24.4% vs 16.0%, p=0.55), and MAP (97.5 vs 92.1 p=0.38), were not different. Progression of CLAD occurred in 2 patients. At the end of follow-up, 7/11 patients were alive. Belatacept-based ISR appear to produce reasonable results in LTRs who fail CNI-based ISR. Larger prospective trials appear warranted in lung transplantation.